Maze Therapeutics Inc stock is traded at $32.53, with a volume of 643,886. It is down -2.55% in the last 24 hours and up +23.08% over the past month. Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Previous Close:
$33.38
Open:
$33.43
24h Volume:
643,886
Relative Volume:
1.37
Market Cap:
$1.81B
Revenue:
$2.50M
Net Income/Loss:
-$131.12M
P/E Ratio:
-
EPS:
-$2.84
Net Cash Flow:
-$112.73M
1W Performance:
+1.88%
1M Performance:
+23.08%
6M Performance:
+22.48%
1Y Performance:
+7.47%
1-Day Range:
$31.83$34.00
1-Week Range:
$29.75$34.00
52-Week Range:
$21.95$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(650) 850-5070Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS